Studies & Results
BCIRG 101
Open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as therapy for advanced breast cancer in women with tumors over-expressing the HER2-neu proto-oncogene
Presentations
ESMO/ECCO Congress, 2002
Bauer-Kosinska B, Pienkowski T, Miskiewicz Z, et al
Valvular, systolic and diastolic cardiac function in metastatic breast cancer patients, receiving combination of trastuzumab and non-anthracycline chemotherapy treatment - 1 year follow up.
Publications
Johnson S, Park H, Gross C, et al.: Use of Alternative Medicine for Cancer and Its Impact on Survival
J Natl Cancer Inst 110, 2018
Baselga J, Im S, Iwata H, et al.: Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Onc 18:904-916, 2017
Ling L, Zhanyu P: Progression-free survival and time to progression as real surrogate endpoints for overall survival in advanced breast cancer: A meta-analysis of 37 trials.
Clinical Breast Cancer 0, 2017
Holch P, Warrington L, Bamforth L, et al.: Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment .
Annals of Oncology 28:2305-2311, 2017
Sledge G, Toi M, Neven P, et al.: MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
J Clin Onco 35:2875-2884, 2017
Pegram MD, Pienkowski T, Northfelt DW, et al: Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer.
J Natl Cancer Inst 96:759–769, 2004
Martinez A, Mateu M: Papel de la radioterapia en el tratamiento del carcinoma in situ
de mama
Oncologia (Barc.) 29:34-40, 2006
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
ESMO/ECCO Congress, 2002
Bauer-Kosinska B, Pienkowski T, Miskiewicz Z, et al
Valvular, systolic and diastolic cardiac function in metastatic breast cancer patients, receiving combination of trastuzumab and non-anthracycline chemotherapy treatment - 1 year follow up.
Publications
Johnson S, Park H, Gross C, et al.: Use of Alternative Medicine for Cancer and Its Impact on Survival J Natl Cancer Inst 110, 2018
Baselga J, Im S, Iwata H, et al.: Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Onc 18:904-916, 2017
Ling L, Zhanyu P: Progression-free survival and time to progression as real surrogate endpoints for overall survival in advanced breast cancer: A meta-analysis of 37 trials. Clinical Breast Cancer 0, 2017
Holch P, Warrington L, Bamforth L, et al.: Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment . Annals of Oncology 28:2305-2311, 2017
Sledge G, Toi M, Neven P, et al.: MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Onco 35:2875-2884, 2017
Pegram MD, Pienkowski T, Northfelt DW, et al: Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. J Natl Cancer Inst 96:759–769, 2004
Martinez A, Mateu M: Papel de la radioterapia en el tratamiento del carcinoma in situ de mama Oncologia (Barc.) 29:34-40, 2006
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org